0001599298-22-000005.txt : 20220105
0001599298-22-000005.hdr.sgml : 20220105
20220105160145
ACCESSION NUMBER: 0001599298-22-000005
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220103
FILED AS OF DATE: 20220105
DATE AS OF CHANGE: 20220105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clark Kenneth A
CENTRAL INDEX KEY: 0001561736
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36866
FILM NUMBER: 22511040
MAIL ADDRESS:
STREET 1: C/O PHARMACYCLICS, INC.
STREET 2: 995 EAST ARQUES AVE.
CITY: SUNNYVALE
STATE: CA
ZIP: 94085
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Summit Therapeutics Inc.
CENTRAL INDEX KEY: 0001599298
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-514-7149
MAIL ADDRESS:
STREET 1: ONE BROADWAY
STREET 2: 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Therapeutics plc
DATE OF NAME CHANGE: 20150219
FORMER COMPANY:
FORMER CONFORMED NAME: Summit Corp plc
DATE OF NAME CHANGE: 20140205
4
1
wf-form4_164141648612518.xml
FORM 4
X0306
4
2022-01-03
0
0001599298
Summit Therapeutics Inc.
SMMT
0001561736
Clark Kenneth A
C/O SUMMIT THERAPEUTICS INC.
ONE BROADWAY, 14TH FLOOR
CAMBRIDGE
MA
02142
1
0
0
0
Stock Option (right to buy)
2.82
2022-01-03
4
A
0
25000
A
2032-01-03
Common Stock
25000.0
25000
D
Stock Option (right to buy)
2.82
2022-01-03
4
A
0
58510
1.13
A
2032-01-03
Common Stock
58510.0
83510
D
The option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022.
Not applicable.
The option was issued on January 3, 2022. The shares underlying the option are scheduled to vest in four equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022.
The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $66,000.
/s/ Kenneth A. Clark
2022-01-05